NCT07197866From ClinicalTrials.govRecruiting

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

An Open-Label Extension, Multi-Centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants With Multiple System Atrophy

Multiple System Atrophy

At a glance

Phase: Phase 2
Study type: Interventional
Sponsor: Teva Branded Pharmaceutical Products R&D LLC
Enrolment target: 200
Started: 30 September 2025
Main results due: 3 May 2029
Study sites: 40
Registry updated: 28 September 2026

Can you take part?

Aged 30 years and over.
Open to any sex.
You need the condition being studied — healthy volunteers are not accepted.

These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.

Read the full eligibility criteria

Inclusion Criteria:

* Completion of the treatment period and the week 48(V9) visit of the double-blind trial (TV56286-NDG-20039) whilst remaining compliant with trial requirements
* Females of childbearing potential may be included only if they have a negative pregnancy test at the baseline visit
* Females of childbearing potential whose male partners are potentially fertile (ie, no vasectomy) must use highly effective birth control methods for the duration of the trial and for 28 days after the last does of IMP
* Males who are potentially fertile/reproductively competent (not surgically \[eg, vasectomy\] or congenitally sterile) and their female partners who are of childbearing potential must use, together with their female partners, highly effective birth control methods for the duration of the trial and for 28 days after the last dose of investigational medicinal product

NOTE - Additional criteria apply, please contact the investigator for more information

Exclusion Criteria:

* Is a female participant who is pregnant, plans to become pregnant, or is breastfeeding during the trial
* Is of a vulnerable population (eg, people kept in detention or jail)
* Is using or consuming any prohibited concomitant medications within the specified exclusionary windows of this trial

Note - Additional criteria apply, please contact the investigator for more information

What this study is about

In the sponsor’s own words, from the registry.

The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA).

A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286.

The planned total duration of the trial is approximately 100 weeks.

Study sites(40)

Teva Investigational Site 15554
La Jolla, California, United States
Recruiting
Teva Investigational Site 15544
Boca Raton, Florida, United States
Recruiting
Teva Investigational Site 15555
Tampa, Florida, United States
Recruiting
Teva Investigational Site 15550
Chicago, Illinois, United States
Recruiting
Teva Investigational Site 15546
Kansas City, Kansas, United States
Recruiting
Teva Investigational Site 15549
New York, New York, United States
Recruiting
Teva Investigational Site 15551
New York, New York, United States
Recruiting
Teva Investigational Site 15553
Durham, North Carolina, United States
Recruiting
Teva Investigational Site 15548
Pittsburgh, Pennsylvania, United States
Recruiting
Teva Investigational Site 15543
Spokane, Washington, United States
Recruiting
Teva Investigational Site 35290
Bordeaux, France
Recruiting
Teva Investigational Site 35289
Marseille, France
Recruiting
Teva Investigational Site 35291
Paris, France
Recruiting
Teva Investigational Site 35292
Toulouse, France
Recruiting
Teva Investigational Site 32818
Dresden, Germany
Recruiting
Teva Investigational Site 32822
Düsseldorf, Germany
Recruiting
Teva Investigational Site 32825
Kassel, Germany
Recruiting
Teva Investigational Site 32824
Marburg, Germany
Recruiting
Teva Investigational Site 32820
München, Germany
Recruiting
Teva Investigational Site 32819
Münster, Germany
Recruiting
Teva Investigational Site 80203
Haifa, Israel
Recruiting
Teva Investigational Site 80204
Tel Aviv, Israel
Recruiting
Teva Investigational Site 30299
Bologna, Italy
Recruiting
Teva Investigational Site 30297
Catania, Italy
Recruiting
Teva Investigational Site 30298
Milan, Italy
Recruiting
Teva Investigational Site 30294
Padova, Italy
Recruiting
Teva Investigational Site 30296
Roma, Italy
Recruiting
Teva Investigational Site 30295
Salerno, Italy
Recruiting
Teva Investigational Site 84139
Fuchū, Japan
Recruiting
Teva Investigational Site 84137
Niigata, Japan
Recruiting
Teva Investigational Site 84138
Sagamihara, Japan
Recruiting
Teva Investigational Site 84141
Sanda-shi, Japan
Recruiting
Teva Investigational Site 84135
Sendai, Japan
Recruiting
Teva Investigational Site 31324
Barcelona, Spain
Recruiting
Teva Investigational Site 31323
Barcelona, Spain
Recruiting
Teva Investigational Site 31321
Barcelona, Spain
Recruiting
Teva Investigational Site 31327
Madrid, Spain
Not yet recruiting
Teva Investigational Site 31320
Pamplona, Spain
Recruiting
Teva Investigational Site 31322
Seville, Spain
Recruiting
Teva Investigational Site 31319
Valencia, Spain
Recruiting

Showing 40 of 40 sites. 39 of the 40 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.

Source: ClinicalTrials.gov record NCT07197866. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Not the right study?

Answer three questions and see the studies recruiting near you, in plain language.

Find a study for me